With the implementation of a new manufacturing process, the maintenance dose for Nulojix (belatacept) will be changed to 6 mg/kg every 4 weeks.

For approximately one to two months starting September 2022, Nulojix from both the previous and the new manufacturing processes will coexist on the market.

Healthcare professionals must carefully check the dose for the specific product to be administered, to make appropriate adjustments for weight-based dosing calculations. 

The dosage during the induction phase (i.e. the first four months post-transplant) is unchanged (10 mg/kg).